Tyler Rose
About Tyler Rose
Tyler H. Rose (age 64) has served on Rexford’s board since February 2015 and is the Lead Independent Director, Audit Committee Chair, and a member of the Nominating & Corporate Governance Committee; he is nominated to become Independent Chairman following the 2025 Annual Meeting, subject to re‑election . Rose is President and Chief Financial Officer of IQHQ, Inc. (private life science real estate), and formerly President, EVP & CFO of Kilroy Realty; earlier roles include senior finance positions at Irvine Apartment Communities and The Irvine Company, with prior investment banking at J.P. Morgan and an early career at GE . He holds a BA in Economics from UC Berkeley and an MBA from the University of Chicago Booth School of Business . The board has determined he is independent under NYSE standards, and he qualifies as an “audit committee financial expert” .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| IQHQ, Inc. | President & Chief Financial Officer | Jan 2024 – Present | Private life science real estate developer; finance and operations leadership |
| Kilroy Realty (NYSE: KRC) | President | 2020 – 2023 | Led public REIT; executive oversight |
| Kilroy Realty | EVP & Chief Financial Officer | 2009 – 2020 | Finance, capital allocation, reporting |
| Kilroy Realty | SVP & Treasurer | 1997 – 2009 | Corporate finance, treasury |
| Irvine Apartment Communities | SVP, Corporate Finance; Treasurer (appointed 1996) | 1995 – 1997 | Corporate finance, treasury |
| The Irvine Company | VP, Corporate Finance | 1994 – 1995 | Corporate finance |
| J.P. Morgan & Co. | Real Estate Corporate Finance; VP Australia M&A | 1986 – 1994 | Real estate corporate finance; M&A leadership |
| General Electric Company | Financial Analyst | Early career | Financial analysis |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Fisher Center for Real Estate & Urban Economics (UC Berkeley) | Policy Advisory Board | Not specified | Advisory role to academic center |
| Other public company boards | None | — | — |
Board Governance
- Roles: Lead Independent Director; expected to be appointed Independent Chairman after 2025 Annual Meeting (subject to re‑election) .
- Committee assignments: Audit (Chair); Nominating & Corporate Governance (Member). Audit members: Rose (Chair), Ingram, Morris, Kleiman; Audit meetings 4 (2024), attendance 100% . Nominating & Corporate Governance meetings 2 (2024), attendance 100% .
- Independence and attendance: Board independence 5 of 7 post‑meeting; 2024 director attendance 97.5%, and each incumbent attended 100% of regularly scheduled Board and committee meetings; Rose presides over executive sessions since April 2022 .
- Lead Independent Director responsibilities include advising on agenda/materials, presiding over executive sessions, and communicating feedback; board approved Rose as future Chairman to separate Chair and CEO roles for stronger oversight .
- Audit Committee Report signed by Rose as Chair, confirming oversight of 2024 financials and auditor independence .
Fixed Compensation
| Component | 2024 Amount | Details |
|---|---|---|
| Cash fees | $150,000 | Includes annual retainer and committee chair fees; Q4 fees paid Jan 2025 |
| Stock awards (restricted common) | $149,991 | 3,357 shares granted June 11, 2024; grant‑date fair value under ASC 718; vests at earlier of next annual meeting or first anniversary |
| Total | $299,991 | Sum of cash and stock |
Director stock ownership guideline: minimum 5× annual cash retainer (excluding committee/lead fees); as of April 14, 2025, all non‑employee directors either meet guidelines or have time remaining to comply by their five‑year window .
Performance Compensation
| Metric | Plan feature | 2024 Director Program |
|---|---|---|
| Performance equity (PSUs/options) | Not disclosed for directors | Annual grants are time‑based restricted stock; no performance metrics disclosed for directors |
Other Directorships & Interlocks
- Current public company directorships: None .
- Potential interlocks: None disclosed with REXR competitors/suppliers/customers; related‑party transaction review overseen by Audit Committee (which Rose chairs) .
- Legal proceedings: No material legal proceedings involving any director; none adverse to REXR .
Expertise & Qualifications
- Audit committee financial expert; financial literacy affirmed; extensive real estate, finance, and accounting expertise; capital allocation and REIT operations experience .
- Executive leadership across public REITs and private real estate; human capital/compensation oversight experience via board roles; technology/cyber oversight is board‑wide with Nominating & Corporate Governance chair leading, and Audit overseeing cybersecurity risk .
Equity Ownership
| Holder | Beneficially Owned (shares/units) | % of Shares Outstanding | Notes |
|---|---|---|---|
| Tyler H. Rose | 26,666 | <1% | As of April 3, 2025; address c/o REXR |
| Restricted common stock held | 3,357 | — | As of Dec 31, 2024 for each non‑employee director; from June 11, 2024 grant |
| Hedging/pledging | Prohibited | — | Policy prohibits officers/directors from hedging/pledging company stock |
| Section 16 compliance | No delinquencies | — | Only Co‑CEOs had one late Form 4 each; no issues noted for Rose |
Governance Assessment
- Strengths
- Independence and leadership: Lead Independent Director and Audit Chair with planned elevation to Independent Chairman, supporting robust oversight and separation of chair/CEO roles .
- Attendance and engagement: 100% committee attendance; presides over executive sessions; board‑wide strong attendance metrics .
- Financial oversight: Audit Committee chaired by Rose; 2024 Audit Report indicates thorough review of financials and auditor independence; clear pre‑approval policy and rotation of lead partners .
- Alignment: Ownership guidelines for directors; time‑based equity granted annually; prohibition on hedging/pledging; no related‑party transactions involving Rose disclosed .
- Watch items
- External executive role: Concurrent service as President & CFO of IQHQ (private life science developer) increases time commitments; while no conflicts are disclosed, ongoing monitoring is prudent for potential overlaps or transactions requiring Audit Committee review .
- Say‑on‑pay environment: 2024 NEO say‑on‑pay support declined to ~62%, prompting program changes; while not a director‑pay issue, shareholder sensitivity to compensation practices may heighten scrutiny of overall governance under Rose’s chairmanship .
- Red flags
- None disclosed for Rose: no legal proceedings, no pledging/hedging, no related‑party transactions, no Section 16 delinquencies .